Zymergen Revenue and Competitors
Estimated Revenue & Valuation
- Zymergen's estimated annual revenue is currently $19.6M per year.
- Zymergen received $400.0M in venture funding in December 2018.
- Zymergen's estimated revenue per employee is $150,846
- Zymergen's total funding is $974.1M.
- Zymergen's current valuation is $562.2M. (January 2022)
Employee Data
- Zymergen has 130 Employees.
- Zymergen grew their employee count by -56% last year.
Zymergen's People
| Name | Title | Email/Phone |
|---|
Zymergen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $356.8M | 1407 | -21% | $1.8B | $1.5B |
What Is Zymergen?
Founded in 2013 and based in the San Francisco Bay Area, Zymergen integrates automation, machine learning, and genomics to rapidly accelerate the pace of scientific advancement. We treat the genome as a search space, leveraging machine learning to make discoveries far beyond the bounds of human intuition. In doing so, we deliver economic value, material diversity and performance capabilities not previously possible. Want to join the team Apply at zymergen.com/careers
keywords:saas, Biotechnology,Cleantech,Hardware,Hardware Peripherals,Healthcare,Pharmaceuticals,Robotics,Solar Power,Wind Power
$974.1M
Total Funding
130
Number of Employees
$19.6M
Revenue (est)
-56%
Employee Growth %
$562.2M
Valuation
N/A
Accelerator
Zymergen News
Zymergen Inc's score of 41 means it scores higher than 41% of stocks in the industry. Zymergen Inc also received an overall rating of 37,...
After zooming higher yesterday, shares of synthetic-biology specialist Zymergen (ZY 8.70%) are moving swiftly in the other direction today.
After shares of Zymergen soared 23% yesterday, investors seem content to collect profits and run during today's trading session.
EMERYVILLE, Calif., May 4, 2021 /PRNewswire/ -- Biofacturing leader Zymergen today announced Aindrea Campbell is joining the company as Chief Manufacturing Officer, developing and leading Zymergen's global manufacturing and supply chain activities. "Aindrea has a proven track record of runnin ...
Shares of Zymergen rose more than 21% in the company's first day of trading on the Nasdaq, closing at $37.65 apiece. At that price, the synthetic biology company was worth nearly $3.6 billion based on the number of shares outstanding, compared with the $2 billion valuation it received from priva ...
Other Companies in Emeryville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $44M | 134 | 8% | N/A |
#2 | $39.4M | 136 | 5% | N/A |
#3 | $20M | 138 | 1% | N/A |
#4 | $32.3M | 140 | 11% | N/A |
#5 | $53M | 147 | 7% | N/A |
Zymergen Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-06-17 | $44.0M | A | Data Collective | Article |
| 2016-10-12 | $130.0M | B | SoftBank Group | Article |
| 2018-12-14 | $400.0M | C | SoftBank Vision Fund | Article |